Canada markets closed

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.36-0.07 (-1.29%)
At close: 4:00PM EDT
5.49 +0.13 (+2.43%)
After hours: 05:29PM EDT

Heat Biologics, Inc.

627 Davis Drive
Suite 400
Morrisville, NC 27560
United States
919 240 7133
http://www.heatbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey Alan Wolf J.D.Founder, Chairman, CEO & Pres1.16MN/A1963
Mr. William L. OstranderCFO & Sec.271.92kN/A1968
Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardN/AN/AN/A
Colonel George E. Peoples Jr., F.A.C.S., FACS, M.D.Chief Medical AdvisorN/AN/AN/A
Dr. Anthony M. Manning Ph.D.Chief Scientific AdvisorN/AN/A1962
Dr. Paul W. Tebbey M.B.A., Ph.D.Sr. VP of Product Devel. & Portfolio StrategyN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Corporate Governance

Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.